The article documents and analyzes patients organizations- and groups of activists’ “evidence-based activismâ€, and the compound dynamic interplay between politics of illness and politics of knowledge it entails in the four condition areas studied: ADHD, Alzheimer, rare diseases...

Analyses the role of European patients’ organizations in the process of Europeanization of healthcare policies by exploring the types of organizations constituted by European patients’ organizations and the form of activism they develop.

Cambodia is expected to graduate from Least Developed Country status soon, at which time it will be required to make patents available for pharmaceutical products and processes to meet its obligations under the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS). Given its...

The United States government is running a campaign to characterize other industrialized countries as free riding on high U.S. pharmaceutical prices and innovation in new drugs. The campaign is based on the argument that lower prices imposed by price controls in these countries do not pay for...

This paper presents a historical perspective on the evolution of relationships between the pharmaceutical industry and physicians in two countries, the United States and Finland. Despite divergence early the twentieth century, and the absence of any large pharmaceutical firms based in Finland,...

Canada has strengthened intellectual property (IP) protections for pharmaceutical drugs several times over the last three decades. These changes were intended to lengthen the period of market exclusivity for new brand drugs and thereby allow them to earn additional sales revenues that could be...

Cambodia is expected to graduate from Least Developed Country status soon, at which time it will be required to make patents available for pharmaceutical products and processes to meet its obligations under the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS). Given its...

Over the past 35 years, patients have suffered from a largely hidden epidemic of side effects from drugs that usually have few offsetting benefits. The pharmaceutical industry has corrupted the practice of medicine through its influence over what drugs are developed, how they are tested, and how...

Data indicate that the widely touted “innovation crisis” in pharmaceuticals is a myth. The real innovation crisis, say Donald Light and Joel Lexchin, stems from current incentives that reward companies for developing large numbers of new drugs with few clinical advantages over existing ones

Navigating the Evidence: Communicating Canadian Health Policy in the Media is a compilation of the EvidenceNetwork commentaries published in major newspapers in 2014, written by experts in the health policy field. These Op-Eds highlight the most recent evidence on a wide range of topics,...